Related Experiment Videos
Suramin inhibits growth and transforming growth factor-beta 1 (TGF-beta 1) binding in osteosarcoma cell lines
P Kloen1, C L Jennings, M C Gebhardt
1Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, 02114.
Abstract:
Autocrine production of growth factors has been shown to be involved in the multistep process of tumorigenesis. The ability of suramin, a polyanionic anti-parasitic drug, to block growth factor-induced cell proliferation makes it a potential antineoplastic drug. We studied the effects of suramin on seven osteosarcoma cell lines. Using clinically achievable concentrations of suramin (50-400 micrograms/ml), we found a time- and dose-dependent inhibition of [3H]thymidine incorporation. We also showed that suramin is able, dose-dependently, to prevent binding of transforming growth factor (TGF)-beta 1 to its receptors. DNA synthesis inhibition by suramin was attenuated by TGF-beta 1 in some cell lines. Two cell lines that were inhibited by TGF-beta 1 were affected similarly by suramin as cell lines that were stimulated by TGF-beta 1. In conclusion, in five out of seven osteosarcoma cell lines, we showed a correlation between inhibition of growth factor-stimulated mitogenesis and binding of TGF-beta 1 to its receptor. Similar effects in TGF-beta 1-inhibited osteosarcoma cell lines suggest involvement of other mechanisms and/or growth factors. However, suramin proves to be a potent inhibitor of osteosarcoma cell proliferation in vitro.
Insights
Suramin effectively inhibits osteosarcoma cell proliferation by blocking growth factor signaling. This drug shows promise as an antineoplastic agent by interfering with transforming growth factor-beta 1 binding.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Autocrine growth factor production is crucial in tumorigenesis.
- Suramin, an anti-parasitic drug, inhibits growth factor-induced cell proliferation.
- This suggests suramin's potential as an antineoplastic agent.
Purpose of the Study:
- To investigate the effects of suramin on seven osteosarcoma cell lines.
- To determine suramin's efficacy in inhibiting osteosarcoma cell proliferation in vitro.
- To explore the mechanism of suramin's action, particularly its interaction with transforming growth factor-beta 1 (TGF-β1).
Main Methods:
- Treatment of seven osteosarcoma cell lines with clinically achievable concentrations of suramin (50-400 µg/ml).
- Measurement of [3H]thymidine incorporation to assess DNA synthesis inhibition.
- Evaluation of suramin's effect on the binding of TGF-β1 to its receptors.
Main Results:
- Suramin demonstrated a time- and dose-dependent inhibition of [3H]thymidine incorporation in osteosarcoma cells.
- Suramin dose-dependently prevented the binding of TGF-β1 to its receptors.
- Inhibition of DNA synthesis by suramin was partially reversed by TGF-β1 in some cell lines.
Conclusions:
- Suramin is a potent inhibitor of osteosarcoma cell proliferation in vitro.
- A correlation was observed between growth factor-stimulated mitogenesis inhibition and TGF-β1 receptor binding in five of seven cell lines.
- The involvement of other mechanisms or growth factors is suggested in TGF-β1-inhibited cell lines.